Advancements in Targeted Radiopharmaceuticals: Innovations in Diagnosis and Therapy for Enhanced Cancer Management

Area of Science:

• Nuclear medicine
• Oncology
• Radiochemistry

Background:

• Radiopharmaceuticals (RPhs) integrate radioactive isotopes into carrier molecules for precise cancer diagnosis and therapy.
• Recent advancements focus on novel probe design and click chemistry for improved RPh synthesis and targeting efficiency.

Purpose of the Study:

• To systematically review recent advances in radiopharmaceutical development for cancer diagnosis and therapy.
• To explore new targets, delivery systems, and therapeutic strategies in precision oncology.

Main Methods:

• Literature synthesis from multiple databases (Jan 2014 - Apr 2025).
• Focus on diagnostic (PET, SPECT) and therapeutic (alpha, beta emitters) applications.
• Analysis of clinically approved agents and emerging targets/delivery systems.

Main Results:

• Clinically approved RPhs like 177Lu-DOTATATE and 177Lu-PSMA-617 show efficacy in specific cancers.
• Emerging targets include fibroblast activation protein, CXCR4, and gastrin-releasing peptide receptors.
• Nanotechnology and combination therapies (TRT with chemo/immunotherapy) show promise.

Conclusions:

• Radiopharmaceuticals offer transformative potential in precision oncology.
• Challenges in production, regulation, and AI integration need addressing.
• Future directions include theranostics, predictive modeling, and novel targeting strategies for enhanced cancer management.